Aditxt Inc (ADTX) Actualités

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt...

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Form 8-K - Current report

Form 8-K - Current report

Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations...

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Event to Focus on the Status of the Acquisition, Plans Post-Acquisition for Evofem, and Q&A Aditxt, Inc. (“Aditxt” or the “Company”...

Form 8-K - Current report

Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval

Appili has a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense...

Form 8-K - Current report

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Aditxt, Inc. (“Aditxt” “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced...

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Aditxt, Inc. (“Aditxt” ) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B3 - Prospectus [Rule 424(b)(3)]